Patent Ductus Arteriosus Response to Treatment by Course and Associations with Perinatal and Clinical Factors

Austin D Rutledge1, Amy E Wahlquist2,3, Ekta U Patel4

  • 1Department of Pediatrics, Medical University of South Carolina, Charleston, South Carolina.

Insights

Chronological age at treatment initiation, not other factors, predicted patent ductus arteriosus (PDA) closure in preterm infants. Older infants were less likely to achieve PDA closure or response to medical treatment.

Area of Science:

  • Neonatal Medicine
  • Pediatric Cardiology

Background:

  • Patent ductus arteriosus (PDA) is a common condition in preterm infants.
  • Medical management with acetaminophen and indomethacin is frequently used for PDA treatment.
  • Understanding factors influencing PDA response is crucial for optimizing treatment strategies.

Purpose of the Study:

  • To examine patent ductus arteriosus (PDA) response to medical treatment across multiple courses.
  • To investigate associations between PDA response and various infant factors, including postmenstrual age (PMA), chronological age (CA), gestational age (GA), antenatal steroid exposure (ANS), birthweight (BW), weight at treatment initiation (WT), and PDA/left pulmonary artery (LPA) ratio.

Main Methods:

  • A single-center retrospective cohort study included preterm infants (<37 weeks GA) treated for PDA between 2016 and 2018.
  • Cox proportional hazards regression models were employed to analyze the association between infant factors and PDA response.
  • Data on 289 treatment courses in 132 infants were analyzed.

Main Results:

  • Overall, 64% of infants achieved definitive PDA closure, and 71% showed PDA constriction after treatment.
  • Chronological age (CA) at treatment initiation was a significant predictor: each 7-day increase in CA reduced the likelihood of PDA closure by 59% (p=0.04) and response by 42% (p<0.01).
  • PDA/LPA ratio was associated with treatment-associated PDA closure (p=0.01), with a 0.1 increase reducing closure likelihood by 19%.

Conclusions:

  • PDA closure in this cohort was independent of PMA, GA, ANS, BW, and WT.
  • CA at treatment initiation emerged as a key predictor for both treatment-associated PDA closure and overall PDA response.
  • Most infants experienced PDA constriction rather than complete closure, even after multiple treatment courses.
Abstract

Related Concept Videos

Fetal Circulation01:14

Fetal Circulation

Fetal circulation is a unique system that facilitates the exchange of gases, nutrients, and waste products between the developing fetus and the mother. This intricate process takes place through a special organ called the placenta.
Two umbilical arteries transport blood from the fetus to the placenta. At the placenta, the blood absorbs oxygen and nutrients while simultaneously eliminating waste products. This oxygen-enriched and nutrient-rich blood then returns to the fetus through one...
1.1K
Mitral Stenosis I: Introduction01:22

Mitral Stenosis I: Introduction

Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
19
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
205